Drug Trial Radar · NCT07709910
A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
382
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Nov 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
Conditions
- Participants With Obesity and Knee Osteoarthritis
Interventions
Ribupatide InjectionDrug
Ribupatide Injection
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatmentTime frame: after 68 weeks of continuous treatment, assessed every few weeks
- Percentage change from baseline in body weight after 68 weeks of treatmentTime frame: after 68 weeks of continuous treatment, assessed every few weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.